Rapid Micro BiosystemsRPID
About: Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Employees: 193
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
28% more capital invested
Capital invested by funds: $12.2M [Q2] → $15.6M (+$3.4M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
2.63% less ownership
Funds ownership: 49.32% [Q2] → 46.69% (-2.63%) [Q3]
10% less funds holding
Funds holding: 21 [Q2] → 19 (-2) [Q3]
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Research analyst outlook
We haven’t received any recent analyst ratings for RPID.
Financial journalist opinion
Based on 5 articles about RPID published over the past 30 days